Exagen Inc. has reached a major milestone by completing its 1,000,000th AVISE CTD test, a diagnostic tool for autoimmune and connective tissue diseases. This achievement highlights the company’s ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. There's PBC, there's PSC, and then there's ...
SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the ...
CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief ...
Delivered record total revenue of $15.5 million on the strength of continued ASP expansion and AVISE CTD test volume growth. Expanded AVISE CTD trailing twelve-month ASP to $419, an increase of $42 ...
Autoimmune rheumatic diseases (ARDs) represent a diverse group of conditions in which the immune system mistakenly targets the body’s own tissues, often affecting the musculoskeletal system and ...
The MosaiQ instrument is a next-generation, continuous random-access immunoassay platform offering labs automation, simple workflows, fast, multiplexed results and actionable insights for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback